Santori & Peters Inc. Purchases 11,000 Shares of Pfizer Inc. $PFE

Santori & Peters Inc. boosted its position in shares of Pfizer Inc. (NYSE:PFE) by 37.0% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 40,708 shares of the biopharmaceutical company’s stock after purchasing an additional 11,000 shares during the period. Pfizer comprises 0.4% of Santori & Peters Inc.’s holdings, making the stock its 27th biggest holding. Santori & Peters Inc.’s holdings in Pfizer were worth $987,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in PFE. Bessemer Group Inc. grew its stake in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock worth $3,358,000 after acquiring an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK grew its stake in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock worth $35,817,000 after acquiring an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp bought a new position in Pfizer in the 1st quarter worth about $8,283,000. Westbourne Investments Inc. bought a new position in Pfizer in the 1st quarter worth about $2,411,000. Finally, Bourne Lent Asset Management Inc. grew its stake in Pfizer by 90.8% in the 2nd quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after acquiring an additional 18,200 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.

Pfizer Trading Down 0.3%

NYSE:PFE opened at $24.07 on Thursday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The firm has a 50 day moving average of $24.59 and a 200 day moving average of $24.18. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $136.82 billion, a price-to-earnings ratio of 12.80, a PEG ratio of 0.85 and a beta of 0.55.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company had revenue of $14.65 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the company posted $0.60 earnings per share. Pfizer’s revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, September 20th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Bank of America upped their price target on shares of Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 6th. Berenberg Bank lowered their price target on shares of Pfizer from $28.00 to $25.00 and set a “hold” rating for the company in a research report on Thursday, May 29th. Finally, Morgan Stanley upped their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.